227 related articles for article (PubMed ID: 11583196)
1. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Yamada Y; Shirao K; Ohtsu A; Boku N; Hyodo I; Saitoh H; Miyata Y; Taguchi T
Ann Oncol; 2001 Aug; 12(8):1133-7. PubMed ID: 11583196
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer.
Emi Y; Yamamoto M; Takahashi I; Orita H; Kakeji Y; Kohnoe S; Maehara Y
Surg Today; 2008; 38(11):1013-20. PubMed ID: 18958560
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
4. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer].
Egawa T; Kubota T; Nagashima A; Doi M; Kitano M; Hayashi S; Yoshii H; Saikawa Y; Kitajima M
Gan To Kagaku Ryoho; 2004 Jun; 31(6):877-81. PubMed ID: 15222104
[TBL] [Abstract][Full Text] [Related]
6. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer.
Ohtsu A; Boku N; Tamura F; Muro K; Shimada Y; Saigenji K; Akazawa S; Kitajima M; Kanamaru R; Taguchi T
Am J Clin Oncol; 1998 Aug; 21(4):416-9. PubMed ID: 9708646
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer.
Yamaguchi K; Tada M; Horikoshi N; Otani T; Takiuchi H; Saitoh S; Kanamaru R; Kasai Y; Koizumi W; Sakata Y; Taguchi T;
Gastric Cancer; 2002; 5(2):90-5. PubMed ID: 12111584
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Hainsworth JD; Greco FA
Cancer; 1994 Aug; 74(4):1377-82. PubMed ID: 7914470
[TBL] [Abstract][Full Text] [Related]
11. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer.
Au E; Tan EH; Ang PT
Ann Oncol; 1998 Mar; 9(3):327-9. PubMed ID: 9602268
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
14. A simplified premedication schedule for 1-hour paclitaxel administration.
Tsavaris N; Kosmas C; Vadiaka M
J Support Oncol; 2005; 3(1):77-81. PubMed ID: 15724950
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
[TBL] [Abstract][Full Text] [Related]
16. Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions.
Sasada S; Hirashima T; Nakamura Y; Takimoto T; Furukawa M; Kobayashi M; Nitta T; Matsui K; Kawase I
Int J Clin Oncol; 2007 Aug; 12(4):274-8. PubMed ID: 17701006
[TBL] [Abstract][Full Text] [Related]
17. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
Sato K; Inoue K; Saito T; Kai T; Mihara H; Okubo K; Koh J; Mochizuki H; Tabei T;
Jpn J Clin Oncol; 2003 Aug; 33(8):371-6. PubMed ID: 14523055
[TBL] [Abstract][Full Text] [Related]
19. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
